| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CYFRA21-1 |
| Uniprot No | P |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | aa |
| 氨基酸序列 | full |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CYFRA21-1重组蛋白的模拟参考文献(基于典型研究方向整理，具体文献需通过数据库验证)：
---
1. **文献名称**: "Expression and Purification of Recombinant CYFRA21-1 in *E. coli* for Immunoassay Development"
**作者**: Zhang L, et al.
**摘要**: 本研究报道了通过大肠杆菌表达系统高效生产重组CYFRA21-1蛋白的优化方法，包括密码子优化、包涵体复性及亲和层析纯化。重组蛋白经Western blot和质谱验证，成功用于开发高灵敏度的ELISA检测试剂盒。
---
2. **文献名称**: "Characterization of a Novel Recombinant CYFRA21-1 Antigen for Lung Cancer Diagnostics"
**作者**: Wang Y, et al.
**摘要**: 通过哺乳动物细胞表达系统制备重组CYFRA21-1蛋白，并系统评估其作为诊断标志物的性能。结果显示，重组蛋白与临床样本中天然CYFRA21-1具有相似的免疫反应性，适用于血清学检测标准化。
---
3. **文献名称**: "Comparison of Recombinant vs. Native CYFRA21-1 in Clinical Assay Performance"
**作者**: Müller S, et al.
**摘要**: 研究对比了重组CYFRA21-1与天然蛋白在化学发光检测中的分析性能。重组蛋白表现出更高的批次间一致性和稳定性，证实其作为校准品替代天然蛋白的可行性。
---
**备注**：以上文献为模拟示例，实际引用时建议通过PubMed、Web of Science等平台检索真实文献(关键词：CYFRA21-1、recombinant protein、diagnostic applications)。
CYFRA21-1 is a soluble fragment of cytokeratin 19 (CK19), a structural protein belonging to the intermediate filament family that maintains epithelial cell integrity. Elevated levels of CYFRA21-1 in serum are clinically recognized as a biomarker for non-small cell lung cancer (NSCLC) and other epithelial-derived malignancies. The detection of CYFRA21-1 aids in cancer diagnosis, prognosis assessment, and therapy monitoring.
Recombinant CYFRA21-1 protein is engineered through genetic cloning and expression systems to mimic the native epitopes of the CK19 fragment. Typically, the gene sequence encoding the specific CYFRA21-1 domain (amino acids 311-335) is inserted into prokaryotic (e.g., *E. coli*) or eukaryotic expression vectors. Following fermentation, the protein undergoes purification via chromatography techniques to ensure high purity and immunoreactivity. This recombinant product retains antigenic properties identical to those of naturally occurring CYFRA21-1. enabling its use as a critical component in immunoassays, such as ELISA or chemiluminescent platforms, for calibrating diagnostic kits and validating antibody specificity.
The development of recombinant CYFRA21-1 addresses challenges in standardizing commercial assays, reducing batch-to-batch variability seen with native protein isolates from tissue sources. It also supports research into cytokeratin biology, tumor progression mechanisms, and novel therapeutic targets. Ongoing studies explore its utility in improving early detection rates and personalized treatment strategies for epithelial cancers, underscoring its translational significance in both clinical and biotechnological contexts.
×
